Gastrointestinal January 2, 2024 Alfasigma to acquire Galapagos’ Jyseleca business By PBR Staff Writer This development is part of Galapagos’ strategy to transform into a new biotechnology enterprise with a robust research and development pipeline for treating disease immunology and oncology fields.
Gastrointestinal December 29, 2023 Palisade Bio receives milestone payment for PALI-2108 development By PBR Staff Writer Received through the foundation’s Inflammatory Bowel Disease (IBD) Ventures programme, this payment is part of a priorly disclosed grant under research programme agreement with Giiant Pharma to support
Oncology December 28, 2023 Eli Lilly concludes POINT Biopharma acquisition for $1.4bn By PBR Staff Writer In October this year, Lilly signed a definitive agreement for POINT Biopharma acquisition. POINT Biopharma focuses on developing radioligand treatments for cancer and has a pipeline of such
Research & DevelopmentCardiovascular December 27, 2023 Innovent and SanegeneBio partner for hypertension drug development By PBR Staff Writer Designed based on the Ligand and Enhancer Assisted Delivery (LEAD) platform of SanegeneBio, SGB-3908 is currently in the investigational new drug application (IND)-enabling stage of development. Both Innovent
RegulationOncology December 26, 2023 FDA grants priority review for Daiichi Sankyo-Merck’s lung cancer therapy By PBR Staff Writer A HER3 targeting DXd antibody-drug conjugate (ADC), patritumab deruxtecan is intended for usage in patients with locally advanced or metastatic EGFR-mutated NSCLC, who have been treated with two
Approvals December 22, 2023 SELLAS receives orphan drug designation for PTCL therapy By PBR Staff Writer Currently, SLS009 is under evaluation in a Phase Ib/II trial for patients with r/r PTCL. The study, which is open-label and single-arm, plans to enrol up to 95
Approvals December 21, 2023 Calliditas receives approval for Nefecon to treat IgAN By PBR Staff Writer This marks Nefecon as the first FDA-approved treatment for IgAN. Nefecon is an oral, delayed-release formulation of budesonide, a corticosteroid with potent anti-inflammatory properties. The enteric-coated capsule approval
Research & Development December 20, 2023 LimmaTech, AbVacc sign licensing agreement for S. aureus vaccine candidate By PBR Staff Writer This vaccine is designed for preventing infections caused by the bacterial pathogen Staphylococcus aureus (S. aureus). S. aureus, a Gram-positive bacterium, affects about 30% of people, causing a
Musculoskeletal Disorders December 19, 2023 Allay grants acute pain management drug license to Japan’s Maruishi Pharmaceutical By PBR Staff Writer ATX101 is designed for sustained, localised pain relief post total knee arthroplasty surgery. Under the agreement, Allay will receive an upfront payment and equity investment. It is also
Approvals December 18, 2023 Arcutis Biotherapeutics receives FDA approval for ZORYVE to treat seborrheic dermatitis By PBR Staff Writer ZORYVE foam offers quick disease clearance and major reduction in itch, with nearly 80% of individuals meeting the primary efficacy endpoint of IGA Success and just more than